Cardiac amyloidosis nuclear image. Image courtesy of the Department of Nuclear Medicine, Medical University of Vienna, Austria.
The American Society of Nuclear Cardiology (ASNC) shared an update this week on the shortage of radiotracers for diagnosing transthyretin (ATTR) cardiac amyloidosis. One vendor has reported it should have new tracers available by the end of March.
Supply issues started in January with a shortage of raw materials. ASNC received reports of shortages from several U.S. sites for both technetium-99m pyrophosphate (Tc-99m PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP). ASNC has maintained close contact with radiotracer vendors for updates.
Curium, a manufacturer of PYP and HMDP, reports that its next HMDP release will be in late March, with a company spokesperson confirming to ASNC that a PYP lot was released in mid-February.